Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A financing will support R&D initially in immunology; the first Terray molecule is expected to reach the clinic in 18 months.
GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Eli Lilly has acquired Protomer Technologies, a preclinical startup developing next-generation insulin that senses blood glucose levels and adjusts its activity accordingly. The technology could eliminate the need for multiple insulin injections throughout the day.
Horizon Therapeutics is gaining global rights to an Arrowhead Pharmaceuticals drug for gout. The preclinical drug is the latest RNA interference program that Arrowhead has licensed to a larger pharma company.
Nick Desai, the co-founder and CEO of Heal, announced he would step down on Tuesday. Scott Vertrees, an advisor to the company, will become the company’s new CEO.
The companies will partner on development and commercialization of ARO-AAT, Arrowhead's Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda's position in the AAT-augmentation therapy market.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Kaiser Permanente opened its first medical school in Pasadena, California. Its first class of 50 students will have a mixture of in-person and virtual classes this year.
Seed is a next-generation sequencing test that identifies signs of DNA methylation in sperm as the result of aging, smoking, pollution and other factors.